Two AML patients who did not recover after multiple lines of salvage therapy, including CD38 CAR-T cell therapy, achieved molecular CR treated with CLL1 CAR-T cell therapy (NCT04884984). This evidence concerns the gene CD38 and acute myeloid leukemia.